November 15, 2022 by Aurigene Tech Team Discovery and clinical development of the first small molecule checkpoint inhibitor for cancer therapy
November 15, 2022 by Aurigene Tech Team Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin…
November 15, 2022 by Aurigene Tech Team Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin